BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35869143)

  • 41. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
    Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
    Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncogenic BRAF and KRAS mutations in endosalpingiosis.
    Chui MH; Shih IM
    J Pathol; 2020 Feb; 250(2):148-158. PubMed ID: 31576556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
    Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
    Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
    Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
    Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R; Shih IeM; Kurman RJ
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-grade serous carcinomas of the ovary contain very few point mutations.
    Jones S; Wang TL; Kurman RJ; Nakayama K; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Shih IeM
    J Pathol; 2012 Feb; 226(3):413-20. PubMed ID: 22102435
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Etemadmoghadam D; Azar WJ; Lei Y; Moujaber T; Garsed DW; Kennedy CJ; Fereday S; Mitchell C; Chiew YE; Hendley J; Sharma R; Harnett PR; Li J; Christie EL; Patch AM; George J; Au-Yeung G; Mir Arnau G; Holloway TP; Semple T; Pearson JV; Waddell N; Grimmond SM; Köbel M; Rizos H; Lomakin IB; Bowtell DDL; deFazio A;
    Cancer Res; 2017 Aug; 77(16):4268-4278. PubMed ID: 28646021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal origin of peritoneal implants and lymph node deposits in serous borderline ovarian tumors (s-BOT) with high intratumoral homogeneity.
    Horn LC; Höhn AK; Einenkel J; Siebolts U
    Int J Gynecol Pathol; 2014 Nov; 33(6):592-7. PubMed ID: 25272298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
    Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New therapeutic opportunities for women with low-grade serous ovarian cancer.
    Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
    Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing for
    Sadlecki P; Grzanka D; Grabiec M
    Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 57. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
    Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
    Gwiti P; Vereczkey I; Cundell D; Aslam S; Clench T; Csernák E; Götzer K; Braybrooke J; Sohail M; Melegh Z
    Histopathology; 2017 Nov; 71(5):686-692. PubMed ID: 28543997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
    Wohlmuth C; Djedovic V; Kjaer SK; Jensen A; Glasspool R; Roxburgh P; DeFazio A; Johnatty SE; Webb PM; Modugno F; Lambrechts D; Schildkraut JM; Berchuck A; Thomsen LCV; Bjorge L; Høgdall E; Høgdall CK; Goode EL; Winham SJ; Matsuo K; Karlan BY; Lester J; Goodman MT; Thompson PJ; Pejovic T; Riggan MJ; Lajkosz K; Tone A; May T
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.